COVID-19 has become one of the worst infectious disease outbreaks of recent times, with over 6.3 million cases and 367000 deaths. Our study aims to analyze characteristics, biomarkers changes of patients with COVID-19 and their associations with severity and outcomes of the disease. Laboratory parameters included inflammatory markers such as procalcitonin (PCT), serum ferritin, C-reactive protein (CRP), lactate dehydrogenase (LDH) and interleukin-6 (IL-6). Fifty-two consecutive hospitalized patients in intensive care unit with confirmed COVID-19, in the university Hospital of Mohammed 6 of Marrakech were enrolled in this retrospective study between March 20, 2020, and May20, 2020. Demographics, underlying diseases and laboratory data were collected. 39 (75%) were man and 13 (25%) were woman; the mean age was 58 years, 76, 1% were up to 50 years old. Among all non-survivors, 81% were male. The median course of the disease was 9 days. The most common co morbidity was hypertension (13/52, 25 %) and diabetes (13/52, 25%). Respirator was used in 23 patients (23/52, 44.2%). 78.59% patients had received Hydroxychloroquine+Azythromycine and 15.8% patients had received antiviral medications: lopinavir/ritonavir. The fatality rate was 71.2 % in this population considered critical. On admission, regardless of the severity, majority of patients present an identical level of inflammation marker levels. Levels of serum ferritin (median 845 [IQR 102.5–4275]), CRP (median 174.15 [IQR 5.19–508.39]), PCT (median 0.68 [IQR 0.04– 45]), LDH (median 519.5 [90–1238]), IL6 concerning 7/52 (median 101[IQR 17– 201]. Dynamic changes of biochemical and immunologic biomarkers during progression of COVID-19 across on admission, mid-hospitalization and end-hospitalization. Measurement of inflammatory markers especially CRP, IL-6 and serum ferritin might assist clinicians to evaluate the severity of COVID-19 because the variations of these biomarkers could serve to predict recovery of fatal outcome.